Ophthalmic Drugs Market Research Report - Forecast to 2023

Report / Search Code: MRFR/HC/4298-HCRR  Publish Date: May, 2019

Price

<table>
<thead>
<tr>
<th></th>
<th>1-user PDF : $ 4450.0</th>
<th>Enterprise PDF : $ 6250.0</th>
</tr>
</thead>
</table>

Description:

Ophthalmic Drugs Market Research Report: By Indication (Glaucoma, Retinal Disorder, Others), Class (Antiallergy, Anti-Inflammatory, and Others), Dosage (Eye Drops, Others), Product (Prescription, OTC Drug), Distribution Channel – Global Forecast Till 2023

Market Scenario

Ophthalmic diseases are potential threats to the status of sight of the population. Various retinal diseases such as Wet AMD, Diabetic Macular Edema (DME), diabetic retinopathy, Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV) are growing at an alarming rate worldwide.

It is noted that the rising prevalence of eye diseases is the key factor driving the ophthalmic drugs market. According to the 2017 statistics suggested by the World Health Organization (WHO), around 253 million people are living with vision impairment, out of which 36 million are blind and nearly 217 million have moderate to severe vision impairment. It is also reported that the chronic eye disease is the main cause of vision loss, globally. Globally, glaucoma is the second leading cause of blindness, according to the World Health Organization, and blindness due to glaucoma is six to eight times more common in African Americans than Caucasians.

Various other factors such as growing awareness of eye diseases, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance are continuously contributing to the growth of the global ophthalmic drugs market.

Despite these drivers, there are some issues associated with the ophthalmic drugs market. The high cost associated with a diagnosis of eye diseases, side effects of available treatment options, lack of healthcare insurance, and poor healthcare system in low and middle-income countries may hamper the growth of the market to an extent.

It is estimated that the ophthalmic drugs market is expected to grow at a CAGR 6.0% during the forecast period of 2017–2023.

Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation

Intended Audience
- Pharmaceutical Companies
- Ophthalmology Associations
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institutes
- Academic Institutes and Universities

Segmentation

The global ophthalmic drugs market is segmented on the basis of indication, drug class, type of dosage, product, and distribution channel.

On the basis of indication, the market is classified as glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.

On the basis of drug class, the market is classified as antiallergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others. The anti-inflammatory segment is further segmented into nonsteroidal drugs and steroidal drugs.

On the basis of type of dosage, the market is classified as eye drops, eye solutions, ointments, capsules and tablets, and gels.

On the basis of the product, the market is classified as prescription drugs and OTC drugs.

On the basis of the distribution channel, the market is classified as hospital pharmacies, online pharmacies, drug stores, and others.

Regional Analysis

The Americas dominates the ophthalmic drugs market owing to the presence of patient population, rising prevalence of eye diseases, well-developed technology, high healthcare expenditure, and the presence of the leading players. According to the glaucoma research foundation, in the United States, more than 120,000 are blind because of glaucoma. This accounts for 9 to 12% of all cases of blindness. It is also reported that over 3 million Americans have glaucoma, but only a few of them know they have it. It is also reported that glaucoma accounts for more than 10 million visits to physicians each year. In November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of
intraocular pressure in patients with glaucoma or ocular hypertension. In December 2017, Rhopressa (netarsudil ophthalmic solution) by Aerie Pharmaceuticals has also received FDA approval for the treatment of glaucoma or ocular hypertension.

Europe holds the second position in the ophthalmic drugs market. It is expected that the government support towards research and development expenditure, increasing competition among marketers, and amendments in reimbursement policies in healthcare are likely to drive the European market.

Asia Pacific is the fastest growing ophthalmic drugs market owing to a huge patient pool, increasing demand, and development of the healthcare technology.

The Middle East and Africa hold the lowest share of the global ophthalmic drugs market due to low development, lack of technical knowledge, and poor medical facilities.

**Key Players**


**Contents:**

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Ophthalmic Drugs Market, by treatment
6.1 Introduction
6.2 Drug Class
6.2.1 Market Estimates & Forecast, 2017–2023
6.3 Devices
6.3.1 Market Estimates & Forecast, 2017–2023
6.4 Others
6.4.1 Market Estimates & Forecast, 2017–2023

Chapter 7. Global Ophthalmic Drugs Market, by End-User
7.1 Introduction
7.2 Hospitals
7.2.1 Market Estimates & Forecast, 2017–2023
7.3 Clinics
7.3.1 Market Estimates & Forecast, 2017–2023
7.4 Diagnostic Centers
7.4.1 Market Estimates & Forecast, 2017–2023
7.5 Drug Stores
7.5.1 Market Estimates & Forecast, 2017–2023
7.6 Pharmacies
7.6.1 Market Estimates & Forecast, 2017–2023
7.7 Others
7.7.1 Market Estimates & Forecast, 2017–2023

Chapter 8. Global Ophthalmic Drugs Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 U.S.
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K.
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa

Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments

Chapter 10 Company Profiles
10.1 Actavis Generics
10.1.1 Company Overview
10.1.2 Types Overview
10.1.3 Financials
10.1.4 SWOT Analysis

10.2 Allergan Plc
10.2.1 Company Overview
10.2.2 Types Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis

10.3 Bausch & Lomb Inc.
10.3.1 Company Overview
10.3.2 Types Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis

10.4 Genentech, Inc.
10.4.1 Company Overview
10.4.2 Types/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis

10.5 MERCK & CO., INC.
10.5.1 Company Overview
10.5.2 Types Overview
10.5.3 Financial overview
10.5.4 Key Developments

10.6 Pfizer Inc.
10.6.1 Company Overview
10.6.2 Types Overview
10.6.3 Financial Overview
10.6.4 Key Developments

10.7 Regeneron Pharmaceuticals, Inc.
10.7.1 Overview
10.7.2 Types Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
Chapter 11MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View Point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of the Ophthalmic Drugs Industry

Chapter 12Appendix

LIST OF TABLES

Table 1 Ophthalmic Drugs Industry Synopsis, 2017–2023
Table 2 Ophthalmic Drugs Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Ophthalmic Drugs Market, by Region, 2017–2023, (USD Million)
Table 4 Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 5 Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 6 Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 7 Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 8 Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 9 North America Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 10 North America Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 11 North America Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 12 North America Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 13 North America Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 14 U.S. Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 15 U.S. Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 16 U.S. Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 17 U.S. Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 18 U.S. Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 19 Canada Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 20 Canada Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 21 Canada Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 22 Canada Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 23 Canada Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 24 South America Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 25 South America Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 26 South America Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 27 South America Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 28 South America Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 29 Europe Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 30 Europe Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 31 Europe Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 32 Europe Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 33 Europe Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 34 Western Europe Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Table 35 Western Europe Ophthalmic Drugs Market, by Drug Class, 2017–2023, (USD Million)
Table 36 Western Europe Ophthalmic Drugs Market, by Type of Dosage, 2017–2023, (USD Million)
Table 37 Western Europe Ophthalmic Drugs Market, by Product, 2017–2023, (USD Million)
Table 38 Western Europe Ophthalmic Drugs Market, by Distribution Channel, 2017–2023, (USD Million)
Table 39 Eastern Europe Ophthalmic Drugs Market, by Indication, 2017–2023, (USD Million)
Figure 34 REGENERON PHARMACEUTICALS, INC.: Geographical Revenue